Jannah Theme License is not validated, Go to the theme options page to validate the license, You need a single license for each domain name.
USA

Oppenheimer Initiates Coverage of Fusion Pharmaceuticals (FUSN) with Outperform Recommendation

Fintel reports that on September 29, 2023, Oppenheimer initiated coverage of Fusion Pharmaceuticals (NASDAQ:FUSN) with a Outperform recommendation.

Analyst Price Forecast Suggests 411.97% Upside

As of August 31, 2023, the average one-year price target for Fusion Pharmaceuticals is 13.26. The forecasts range from a low of 9.09 to a high of $21.00. The average price target represents an increase of 411.97% from its latest reported closing price of 2.59.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Fusion Pharmaceuticals is 35MM, an increase of 9,311.14%. The projected annual non-GAAP EPS is -1.96.

What is the Fund Sentiment?

There are 55 funds or institutions reporting positions in Fusion Pharmaceuticals. This is an increase of 2 owner(s) or 3.77% in the last quarter. Average portfolio weight of all funds dedicated to FUSN is 0.30%, an increase of 13.18%. Total shares owned by institutions increased in the last three months by 10.22% to 50,306K shares. The put/call ratio of FUSN is 0.07, indicating a bullish outlook.

What are Other Shareholders Doing?

FUSN / Fusion Pharmaceuticals Inc Shares Held by Institutions

Federated Hermes holds 10,634K shares representing 15.41% ownership of the company. In it’s prior filing, the firm reported owning 5,849K shares, representing an increase of 45.00%. The firm increased its portfolio allocation in FUSN by 125.77% over the last quarter.

Avidity Partners Management holds 5,700K shares representing 8.26% ownership of the company. No change in the last quarter.

Johnson & Johnson holds 3,671K shares representing 5.32% ownership of the company. No change in the last quarter.

Orbimed Advisors holds 3,123K shares representing 4.53% ownership of the company. No change in the last quarter.

Canada Pension Plan Investment Board holds 3,117K shares representing 4.52% ownership of the company. No change in the last quarter.

Fusion Pharmaceuticals Background Information
(This description is provided by the company.)

Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion’s lead program, FPI-1434, is currently in a Phase 1 clinical trial. The Company is advancing a pipeline of targeted radiopharmaceutical cancer therapies for a broad array of tumor types based upon its proprietary platform technology.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Click to Learn More

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Summarize this content to 100 words

Fintel reports that on September 29, 2023, Oppenheimer initiated coverage of Fusion Pharmaceuticals (NASDAQ:FUSN) with a Outperform recommendation. Analyst Price Forecast Suggests 411.97% Upside As of August 31, 2023, the average one-year price target for Fusion Pharmaceuticals is 13.26. The forecasts range from a low of 9.09 to a high of $21.00. The average price target represents an increase of 411.97% from its latest reported closing price of 2.59.

See our leaderboard of companies with the largest price target upside. The projected annual revenue for Fusion Pharmaceuticals is 35MM, an increase of 9,311.14%. The projected annual non-GAAP EPS is -1.96. What is the Fund Sentiment? There are 55 funds or institutions reporting positions in Fusion Pharmaceuticals. This is an increase of 2 owner(s) or 3.77% in the last quarter. Average portfolio weight of all funds dedicated to FUSN is 0.30%, an increase of 13.18%. Total shares owned by institutions increased in the last three months by 10.22% to 50,306K shares. The put/call ratio of FUSN is 0.07, indicating a bullish outlook. What are Other Shareholders Doing? Federated Hermes holds 10,634K shares representing 15.41% ownership of the company. In it’s prior filing, the firm reported owning 5,849K shares, representing an increase of 45.00%. The firm increased its portfolio allocation in FUSN by 125.77% over the last quarter. Avidity Partners Management holds 5,700K shares representing 8.26% ownership of the company. No change in the last quarter.

Johnson & Johnson holds 3,671K shares representing 5.32% ownership of the company. No change in the last quarter. Orbimed Advisors holds 3,123K shares representing 4.53% ownership of the company. No change in the last quarter. Canada Pension Plan Investment Board holds 3,117K shares representing 4.52% ownership of the company. No change in the last quarter. Fusion Pharmaceuticals Background Information(This description is provided by the company.) Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion’s lead program, FPI-1434, is currently in a Phase 1 clinical trial. The Company is advancing a pipeline of targeted radiopharmaceutical cancer therapies for a broad array of tumor types based upon its proprietary platform technology.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
Click to Learn MoreThis story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

https://www.nasdaq.com/articles/oppenheimer-initiates-coverage-of-fusion-pharmaceuticals-fusn-with-outperform Oppenheimer Initiates Coverage of Fusion Pharmaceuticals (FUSN) with Outperform Recommendation

Back to top button